CD274 and cancer: The Society for Immunotherapy of Cancer Annual Meeting reported that treating patients with TLS-positive tumors with a PD-L1-targeted agent plus a multi-kinase inhibitor with anti-angiogenic activity led to clinical responses, even in types of cancer that are usually thought to be resistant to checkpoint inhibitors (113).